# Harmony Biosciences Holdings, Inc.: financial statements, quarterly

HRMY · Nasdaq · CIK 1802665 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/hrmy.md) · [Financials](/companies/hrmy/financials.md) · [Filings](/companies/hrmy/filings.md) · [Insiders](/companies/hrmy/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/hrmy/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [160](/filings/0001558370-24-013803.md) | [168 d](/filings/0001104659-26-018859.md) | [155](/filings/0001558370-25-006394.md) | [173](/filings/0001558370-25-010185.md) | [186](/filings/0001104659-25-105962.md) | [201 d](/filings/0001104659-26-018859.md) | [185](/filings/0001104659-26-056720.md) | [200](/filings/0001104659-26-090090.md) | [239](/filings/0001104659-25-105962.md) | [244 d](/filings/0001104659-26-018859.md) | [215](/filings/0001104659-26-056720.md) | [261](/filings/0001104659-26-090090.md) |
| Cost of revenue | $m | [32.3](/filings/0001558370-24-013803.md) | [43.2 d](/filings/0001104659-26-018859.md) | [27.5](/filings/0001558370-25-006394.md) | [32.1](/filings/0001558370-25-010185.md) | [42.8](/filings/0001104659-25-105962.md) | [54.4 d](/filings/0001104659-26-018859.md) | [32.0](/filings/0001104659-26-056720.md) | [38.2](/filings/0001104659-26-090090.md) | [59.7](/filings/0001104659-25-105962.md) | [68.5 d](/filings/0001104659-26-018859.md) | [44.5](/filings/0001104659-26-056720.md) | [63.2](/filings/0001104659-26-090090.md) |
| Gross profit | $m | [128](/filings/0001558370-24-013803.md) | [125 d](/filings/0001104659-26-018859.md) | [127](/filings/0001558370-25-006394.md) | [141](/filings/0001558370-25-010185.md) | [143](/filings/0001104659-25-105962.md) | [147 d](/filings/0001104659-26-018859.md) | [153](/filings/0001104659-26-056720.md) | [162](/filings/0001104659-26-090090.md) | [180](/filings/0001104659-25-105962.md) | [175 d](/filings/0001104659-26-018859.md) | [171](/filings/0001104659-26-056720.md) | [198](/filings/0001104659-26-090090.md) |
| Research and development | $m | [17.5](/filings/0001558370-24-013803.md) | [30.3 d](/filings/0001104659-26-018859.md) | [22.2](/filings/0001558370-25-006394.md) | [63.6](/filings/0001558370-25-010185.md) | [25.4](/filings/0001104659-25-105962.md) | [34.7 d](/filings/0001104659-26-018859.md) | [34.5](/filings/0001104659-26-056720.md) | [50.2](/filings/0001104659-26-090090.md) | [55.0](/filings/0001104659-25-105962.md) | [49.9 d](/filings/0001104659-26-018859.md) | [69.4](/filings/0001104659-26-056720.md) | [46.6](/filings/0001104659-26-090090.md) |
| Operating income | $m | [64.5](/filings/0001558370-24-013803.md) | [40.2 d](/filings/0001104659-26-018859.md) | [52.0](/filings/0001558370-25-006394.md) | [21.4](/filings/0001558370-25-010185.md) | [61.7](/filings/0001104659-25-105962.md) | [55.7 d](/filings/0001104659-26-018859.md) | [56.2](/filings/0001104659-26-056720.md) | [48.2](/filings/0001104659-26-090090.md) | [65.5](/filings/0001104659-25-105962.md) | [38.6 d](/filings/0001104659-26-018859.md) | [37.3](/filings/0001104659-26-056720.md) | [89.3](/filings/0001104659-26-090090.md) |
| Interest expense | $m | [7.0](/filings/0001558370-24-013803.md) | [4.8 d](/filings/0001558370-24-001466.md) | [4.5](/filings/0001558370-24-006203.md) | [4.4](/filings/0001558370-25-010185.md) | [4.3](/filings/0001104659-25-105962.md) | [4.2 d](/filings/0001104659-26-018859.md) | [3.8](/filings/0001104659-26-056720.md) | [3.6](/filings/0001104659-26-090090.md) | [3.6](/filings/0001104659-25-105962.md) | [3.5 d](/filings/0001104659-26-018859.md) | [3.2](/filings/0001104659-26-056720.md) | [3.1](/filings/0001104659-26-090090.md) |
| Income tax | $m | [13.4](/filings/0001558370-24-013803.md) | [13.1 d](/filings/0001104659-26-018859.md) | [13.5](/filings/0001558370-25-006394.md) | [10.1](/filings/0001558370-25-010185.md) | [16.1](/filings/0001104659-25-105962.md) | [6.7 d](/filings/0001104659-26-018859.md) | [11.6](/filings/0001104659-26-056720.md) | [9.9](/filings/0001104659-26-090090.md) | [16.6](/filings/0001104659-25-105962.md) | [18.3 d](/filings/0001104659-26-018859.md) | [7.2](/filings/0001104659-26-056720.md) | [17.8](/filings/0001104659-26-090090.md) |
| Net income | $m | [38.5](/filings/0001558370-24-013803.md) | [26.6 d](/filings/0001104659-26-018859.md) | [38.3](/filings/0001558370-25-006394.md) | [11.6](/filings/0001558370-25-010185.md) | [46.1](/filings/0001104659-25-105962.md) | [49.5 d](/filings/0001104659-26-018859.md) | [45.6](/filings/0001104659-26-056720.md) | [39.8](/filings/0001104659-26-090090.md) | [50.9](/filings/0001104659-25-105962.md) | [22.5 d](/filings/0001104659-26-018859.md) | [32.5](/filings/0001104659-26-056720.md) | [75.4](/filings/0001104659-26-090090.md) |
| Diluted EPS | $ per share | [0.63](/filings/0001558370-24-013803.md) | not reported | [0.67](/filings/0001558370-25-006394.md) | [0.20](/filings/0001558370-25-010185.md) | [0.79](/filings/0001104659-25-105962.md) | not reported | [0.78](/filings/0001104659-26-056720.md) | [0.68](/filings/0001104659-26-090090.md) | [0.87](/filings/0001104659-25-105962.md) | not reported | [0.55](/filings/0001104659-26-056720.md) | [1.28](/filings/0001104659-26-090090.md) |
| Basic EPS | $ per share | [0.64](/filings/0001558370-24-013803.md) | not reported | [0.68](/filings/0001558370-25-006394.md) | [0.20](/filings/0001558370-25-010185.md) | [0.81](/filings/0001104659-25-105962.md) | not reported | [0.79](/filings/0001104659-26-056720.md) | [0.69](/filings/0001104659-26-090090.md) | [0.88](/filings/0001104659-25-105962.md) | not reported | [0.56](/filings/0001104659-26-056720.md) | [1.30](/filings/0001104659-26-090090.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating, us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [325](/filings/0001558370-23-017060.md) | [312](/filings/0001558370-25-001441.md) | [333](/filings/0001558370-24-006203.md) | [317](/filings/0001558370-24-010956.md) | [387](/filings/0001558370-24-013803.md) | [453](/filings/0001104659-26-018859.md) | [489](/filings/0001558370-25-006394.md) | [546](/filings/0001558370-25-010185.md) | [647](/filings/0001104659-25-105962.md) | [753](/filings/0001104659-26-090090.md) | [589](/filings/0001104659-26-056720.md) | [550](/filings/0001104659-26-090090.md) |
| Current assets | $m | [463](/filings/0001558370-23-017060.md) | [451](/filings/0001558370-25-001441.md) | [480](/filings/0001558370-24-006203.md) | [458](/filings/0001558370-24-010956.md) | [522](/filings/0001558370-24-013803.md) | [579](/filings/0001104659-26-018859.md) | [643](/filings/0001558370-25-006394.md) | [691](/filings/0001558370-25-010185.md) | [839](/filings/0001104659-25-105962.md) | [907](/filings/0001104659-26-090090.md) | [779](/filings/0001104659-26-056720.md) | [814](/filings/0001104659-26-090090.md) |
| Total assets | $m | [778](/filings/0001558370-23-017060.md) | [811](/filings/0001558370-25-001441.md) | [847](/filings/0001558370-24-006203.md) | [858](/filings/0001558370-24-010956.md) | [928](/filings/0001558370-24-013803.md) | [999](/filings/0001104659-26-018859.md) | [1,056](/filings/0001558370-25-006394.md) | [1,108](/filings/0001558370-25-010185.md) | [1,208](/filings/0001104659-25-105962.md) | [1,272](/filings/0001104659-26-090090.md) | [1,272](/filings/0001104659-26-056720.md) | [1,373](/filings/0001104659-26-090090.md) |
| Current liabilities | $m | [112](/filings/0001558370-23-017060.md) | [164](/filings/0001558370-25-001441.md) | [154](/filings/0001558370-24-006203.md) | [147](/filings/0001558370-24-010956.md) | [161](/filings/0001558370-24-013803.md) | [175](/filings/0001104659-26-018859.md) | [175](/filings/0001558370-25-006394.md) | [180](/filings/0001558370-25-010185.md) | [223](/filings/0001104659-25-105962.md) | [252](/filings/0001104659-26-090090.md) | [217](/filings/0001104659-26-056720.md) | [234](/filings/0001104659-26-090090.md) |
| Total liabilities | $m | [296](/filings/0001558370-23-017060.md) | [344](/filings/0001558370-25-001441.md) | [332](/filings/0001558370-24-006203.md) | [320](/filings/0001558370-24-010956.md) | [331](/filings/0001558370-24-013803.md) | [340](/filings/0001104659-26-018859.md) | [335](/filings/0001558370-25-006394.md) | [335](/filings/0001558370-25-010185.md) | [373](/filings/0001104659-25-105962.md) | [401](/filings/0001104659-26-090090.md) | [361](/filings/0001104659-26-056720.md) | [374](/filings/0001104659-26-090090.md) |
| Long-term debt | $m | [182](/filings/0001558370-23-017060.md) | [179](/filings/0001558370-25-001441.md) | [175](/filings/0001558370-24-006203.md) | [171](/filings/0001558370-24-010956.md) | [168](/filings/0001558370-24-013803.md) | [163](/filings/0001104659-26-018859.md) | [158](/filings/0001558370-25-006394.md) | [153](/filings/0001558370-25-010185.md) | [149](/filings/0001104659-25-105962.md) | [144](/filings/0001104659-26-090090.md) | [139](/filings/0001104659-26-056720.md) | [134](/filings/0001104659-26-090090.md) |
| Current portion of debt | $m | [15.0](/filings/0001558370-23-017060.md) | [15.0](/filings/0001558370-25-001441.md) | [15.0](/filings/0001558370-24-006203.md) | [15.0](/filings/0001558370-24-010956.md) | [15.0](/filings/0001558370-24-013803.md) | [16.3](/filings/0001104659-26-018859.md) | [17.5](/filings/0001558370-25-006394.md) | [18.8](/filings/0001558370-25-010185.md) | [20.0](/filings/0001104659-25-105962.md) | [20.0](/filings/0001104659-26-090090.md) | [20.0](/filings/0001104659-26-056720.md) | [20.0](/filings/0001104659-26-090090.md) |
| Shareholders' equity | $m | [481](/filings/0001558370-24-013803.md) | [467](/filings/0001104659-26-018859.md) | [515](/filings/0001558370-25-010185.md) | [539](/filings/0001104659-25-105962.md) | [597](/filings/0001104659-25-105962.md) | [659](/filings/0001104659-26-090090.md) | [721](/filings/0001104659-26-090090.md) | [773](/filings/0001104659-26-090090.md) | [835](/filings/0001104659-25-105962.md) | [870](/filings/0001104659-26-090090.md) | [910](/filings/0001104659-26-090090.md) | [999](/filings/0001104659-26-090090.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [63.1 d](/filings/0001558370-24-013803.md) | [76.7 d](/filings/0001104659-26-018859.md) | [31.1](/filings/0001558370-25-006394.md) | [42.6 d](/filings/0001558370-25-010185.md) | [70.5 d](/filings/0001104659-25-105962.md) | [75.6 d](/filings/0001104659-26-018859.md) | [34.0](/filings/0001104659-26-056720.md) | [79.3 d](/filings/0001104659-26-090090.md) | [109 d](/filings/0001104659-25-105962.md) | [126 d](/filings/0001104659-26-018859.md) | [27.8](/filings/0001104659-26-056720.md) | [92.4 d](/filings/0001104659-26-090090.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001558370-24-013803.md) | [0.1 d](/filings/0001104659-26-018859.md) | [0.0](/filings/0001558370-25-006394.md) | [0.6 d](/filings/0001558370-25-010185.md) | [0.0 d](/filings/0001104659-25-105962.md) | [0.5 d](/filings/0001104659-26-018859.md) | [0.1](/filings/0001104659-26-056720.md) | [0.0 d](/filings/0001104659-26-090090.md) | [0.1 d](/filings/0001104659-25-105962.md) | [0.1 d](/filings/0001104659-26-018859.md) | not reported | not reported |
| Share repurchases | $m | not reported | [50.0 d](/filings/0001104659-26-018859.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [61.2](/filings/0001558370-23-017060.md) | [61.2](/filings/0001558370-24-006203.md) | [60.7](/filings/0001558370-24-010956.md) | [60.7](/filings/0001558370-24-013803.md) | [57.6](/filings/0001558370-25-006394.md) | [57.5](/filings/0001558370-25-010185.md) | [58.1](/filings/0001104659-25-105962.md) | [58.5](/filings/0001104659-26-056720.md) | [58.4](/filings/0001104659-26-090090.md) | [58.7](/filings/0001104659-25-105962.md) | [58.8](/filings/0001104659-26-056720.md) | [58.8](/filings/0001104659-26-090090.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 58,236,393 at 2026-07-31, from the cover of the [10-Q filed 2026-08-04](/filings/0001104659-26-090090.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.